MHRA-licensed medicine · GPhC-registered UK pharmacy

Mounjaro Weight Loss Injections

Mounjaro (tirzepatide) is a once-weekly, prescription-only injection for weight management in eligible adults – prescribed only after an online clinical assessment by our UK pharmacist independent prescriber.

Medically reviewed by Moazma Ahmed, MPharm

Pharmacist Independent Prescriber · GPhC 2069977

Last reviewed:

19th June 2026

Pricing

Mounjaro pricing (per pen / 4 weekly doses)

Each price includes the medication, your online private prescription, needles, alcohol wipes, a sharps bin, tracked cold-chain delivery and ongoing pharmacist support. No subscription and no hidden consultation fees.

Mounjaro 2.5mg

· starter dose

£144

Mounjaro 5mg

£169

Mounjaro 7.5mg

£225

Mounjaro 10mg

£249

Mounjaro 12.5mg

£269

Mounjaro 15mg

· maximum dose

£289

Mounjaro is a prescription-only medicine. Treatment is supplied only where clinically appropriate, after assessment by a UK-registered prescriber. Completing a consultation does not guarantee that treatment will be approved.

Overview

What is Mounjaro and how does it work?

Mounjaro is a prescription-only weight loss injection containing the active ingredient tirzepatide. First developed for type 2 diabetes, it is now licensed in the UK and recommended by NICE for weight management in eligible adults with obesity, or adults who are overweight and have at least one weight-related health condition. It is used alongside a reduced-calorie diet and increased physical activity, and is taken once weekly using a pre-filled pen.

Tirzepatide is a dual GIP and GLP-1 receptor agonist – it acts on two natural gut-hormone pathways that help regulate appetite, fullness and blood sugar. Semaglutide (Wegovy, Ozempic) acts on the GLP-1 pathway only; this dual action is one reason tirzepatide has shown strong results in clinical studies.

How Mounjaro supports weight loss

Reduces appetite by acting on appetite-control centres in the brain.
Increases fullness by slowing how quickly food leaves the stomach.
May reduce cravings, making portion control easier.
Supports blood sugar control, relevant for people with prediabetes or type 2 diabetes.

How much weight could I lose?

In the SURMOUNT-1 trial, participants taking tirzepatide alongside diet and exercise lost, on average, around 20–22.5% of their body weight at the highest dose over 72 weeks. These are trial averages – individual results vary, weight loss is not guaranteed, and Mounjaro is a tool used alongside lifestyle change, not a quick fix.

Eligibility

Who may be suitable for Mounjaro?

Mounjaro may be prescribed for weight management in adults who meet the clinical criteria. You may be eligible if:

You are aged 18 or over
Your BMI is 30 or above, or 27–30 with a weight-related condition (e.g. high blood pressure, high cholesterol, prediabetes, type 2 diabetes, sleep apnoea)
You do not have a medical condition or medicine that makes Mounjaro unsafe for you
You are not pregnant, breastfeeding or planning pregnancy

Who should not take Mounjaro

Mounjaro may not be suitable if you have a personal or family history of medullary thyroid cancer or MEN2, a history of pancreatitis, severe gastrointestinal disease or gastroparesis, are pregnant/breastfeeding/trying to conceive, are under 18, or have had an allergic reaction to tirzepatide. A prescriber must review your full medical history, current medicines, BMI and treatment history before deciding whether treatment is appropriate. Treatment is never approved automatically.

Dosing

Mounjaro dose schedule

Mounjaro follows a gradual dose-escalation schedule to help reduce side effects. You start low and increase over time, only if the previous dose is tolerated and further weight loss is needed.

Dose (once weekly)

Typical timing

Notes

2.5mg

Weeks 1–4

Starting dose

5mg

Week 5 onward

Increase after ≥4 weeks if tolerated

7.5mg

After ≥4 weeks at 5mg

Step up if needed

10mg

After ≥4 weeks

Step up if needed

12.5mg

After ≥4 weeks

Step up if needed

15mg

Maximum dose

Maintenance if suitable and tolerated

Many patients settle on 5mg or 10mg as a maintenance dose. Never increase your dose sooner than directed (usually no faster than every 4 weeks) and do not exceed 15mg weekly. Inject once weekly on the same day, with or without food, rotating the injection site (abdomen, thigh or upper arm). Store unused pens in the fridge (2–8°C); a pen in use can be kept at room temperature for up to 30 days. Dispose of pens and needles in the sharps bin provided.

Missed dose
If you miss a dose, take it within 4 days (96 hours). If more than 4 days have passed, skip it and take your next dose on the usual day. Never take two doses to make up for a missed one.

Safety

Side effects and safety

Like all medicines, Mounjaro can cause side effects. For most people these are mild to moderate and improve as the body adjusts. The most common are digestive symptoms, especially when starting or increasing the dose.

Common

Nausea, vomiting, diarrhoea, constipation, indigestion, stomach discomfort, reduced appetite, dizziness, fatigue, injection-site reactions, and possible hair thinning during rapid weight loss.

Less common / serious

Gallstones, increased heart rate, low blood sugar (if combined with insulin or sulfonylureas), and — rarely — pancreatitis or a serious allergic reaction.

Most side effects are mild to moderate and may settle as your body adjusts. You should contact a healthcare professional if side effects are severe, persistent or worrying.

Seek urgent medical help
for severe, persistent abdominal pain (possible pancreatitis), yellowing of the skin or eyes, signs of a serious allergic reaction (facial/tongue swelling, difficulty breathing — call 999), or any symptom that feels severe or unusual.

Before surgery or sedation
Tell your surgeon, anaesthetist or endoscopy team that you take tirzepatide — it slows stomach emptying, which matters for general anaesthesia or deep sedation.

Contraception & pregnancy
Tirzepatide can reduce absorption of the oral contraceptive pill. If you use the pill, add a barrier method (e.g. condoms) or switch to a non-oral method for 4 weeks after starting and for 4 weeks after each dose increase. Do not use Mounjaro in pregnancy or while breastfeeding, and stop at least 1 month before trying to conceive.

▼ Additional monitoring
Mounjaro is subject to additional safety monitoring. Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Always read the Patient Information Leaflet supplied with your medicine.

Compare

Mounjaro vs Wegovy vs Ozempic

Mounjaro

Wegovy

Ozempic

Active ingredient

Tirzepatide

Semaglutide

Action

GIP + GLP-1 (dual)

GLP-1

Licensed for

Weight management

Type 2 diabetes

Frequency

Once weekly

Trial average weight loss

~20–22.5% (highest dose)

~15% (2.4mg)

Lower (diabetes doses)

All are prescription-only and used alongside diet and physical activity. Ozempic is the same active ingredient as Wegovy but licensed for type 2 diabetes. Which option is most suitable depends on your history, preferences and how you respond – your prescriber can help you decide. If Mounjaro is not suitable, alternatives such as Wegovy may be considered. See Wegovy injections.

How it works

How our Mounjaro service works

1. Online consultation

Complete a short medical questionnaire covering your health, weight, BMI, conditions and current medicines. Answer honestly so our clinicians can assess suitability.

2. Prescriber review

A UK pharmacist independent prescriber reviews your answers, may confirm details with you, and decides whether treatment is clinically appropriate. There is no charge if we cannot prescribe.

3. Dispensing & delivery

If approved, we dispense from UK stock and ship in tracked, temperature-controlled packaging, including needles, a sharps bin and the Patient Information Leaflet.

4. Aftercare

Ongoing support with dose changes, side-effect advice, monitoring and reviews. With your consent, we can share a summary with your NHS GP for joined-up care.

Eligibility

Can I get Mounjaro on the NHS?

Tirzepatide (Mounjaro) is being introduced on the NHS for weight management through a phased, multi-year rollout that prioritises those with the highest clinical need. Since March 2025 it has been available via specialist weight management services, and from 2026 it is moving into GP prescribing — but participation is optional and varies between practices, and meeting the criteria does not guarantee access.

In the first phase, NHS eligibility is limited to adults with a BMI of 40 or more (lower for some ethnic groups) and four or more weight-related health conditions, with criteria gradually widening over the rollout. Because NHS access is currently restricted and depends on local services, most people seeking Mounjaro for weight management access it privately, through a regulated service such as ours, after a clinical assessment.

Questions

Frequently asked questions

Is Mounjaro approved for weight loss in the UK?

Yes. Tirzepatide is licensed in the UK and recommended by NICE for weight management in eligible adults. NHS access is currently limited to a phased rollout for those with the highest clinical need, so most people access it privately after a clinical assessment.

How much weight can I lose with Mounjaro?

In the SURMOUNT-1 trial, participants on the highest dose lost on average around 20–22.5% of their body weight over 72 weeks, alongside diet and exercise. Individual results vary and weight loss is not guaranteed.

Do I still need to diet and exercise?

Yes. Mounjaro makes it easier to eat less by reducing appetite, but it works best as part of a reduced-calorie diet, increased activity and ongoing support — it is not a standalone solution.

How long will I take Mounjaro?

There is no fixed course. Some people use it for several months, others longer. Obesity is often a long-term condition, so maintenance treatment may be appropriate. Your prescriber will review your progress and advise.

What are the main side effects?

Most commonly digestive symptoms — nausea, vomiting, diarrhoea and constipation — especially when starting or increasing the dose. Rare but serious risks include pancreatitis and allergic reactions.

Can I use Mounjaro if I take the contraceptive pill?

Tirzepatide can reduce absorption of the pill. Use an additional barrier method, or a non-oral method, for 4 weeks after starting and for 4 weeks after each dose increase. Speak to your prescriber for advice.

What if Mounjaro isn't suitable for me?

If treatment isn’t clinically appropriate, we will tell you and may suggest an alternative such as Wegovy, or recommend you speak to your GP. There is no charge if we cannot prescribe.

Is it the same as Wegovy or Ozempic?

No. Mounjaro contains tirzepatide (dual GIP/GLP-1). Wegovy and Ozempic contain semaglutide (GLP-1 only). Wegovy is licensed for weight management; Ozempic is licensed for type 2 diabetes.

About this information

Medically reviewed by Moazma Ahmed, MPharm

Moazma Ahmed is a UK-registered pharmacist and independent prescriber with expertise in medical weight loss and GLP-1 / GIP treatments. She is Lead Prescriber and Superintendent Pharmacist at Live Well Weight Loss (GPhC 2069977) and is responsible for clinical accuracy across this content.

Last medically reviewed: 19th June 2026· Dispensing & prescribing: Concept Medicine Ltd TA Live Well Pharmacy, GPhC registration 9012516, Unit T3, Enterprise Centre, Ray Street, Huddersfield, HD1 6BL.

References

1. Mounjaro (tirzepatide) Summary of Product Characteristics — electronic medicines compendium (medicines.org.uk/emc).

2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.

3. NICE Technology Appraisal TA1026 — Tirzepatide for managing overweight and obesity (nice.org.uk/guidance/ta1026).

4. NHS England — Weight management injections / interim commissioning guidance (england.nhs.uk).

5. MHRA — Yellow Card scheme (yellowcard.mhra.gov.uk).

This content is for information only and does not replace advice from your prescribing clinician. Mounjaro is a prescription-only medicine, supplied only after prescriber approval and used alongside a reduced-calorie diet and increased physical activity. Individual results vary and no result is guaranteed. Always read the Patient Information Leaflet. Do not use Mounjaro unless it has been prescribed for you.

Start your Mounjaro consultation

Answer a few health questions and our UK pharmacist prescriber will review whether Mounjaro is suitable for you. There’s no charge if we can’t prescribe.